盐酸埃克替尼治疗晚期非小细胞肺癌患者的效果及对免疫功能的影响

Effect of icotinib hydrochloride on patients with advanced non-small cell lung cancer and its influence on immune function

目的探讨盐酸埃克替尼治疗晚期非小细胞肺癌患者的临床效果及免疫功能效果。方法本文选择我院2013年5月～2017年12月收治的33例患者,所有患者均口服盐酸埃克替尼治疗。观察患者临床疗效、免疫功能、不良反应及生存期。结果ⅢB期有效率33.33%,控制率为83.33%,高于Ⅳ期29.63%和70.37%(P<0.05)。治疗后,CD3^+、CD4^+及CD4^+/CD8^+均较治疗前明显升高,而CD8^+较治疗前明显下降(P<0.05)。治疗后不良反应为皮疹39.4%(13/33),恶心、呕吐30.3%(10/33),腹泻21.2%(7/33),食欲下降24.2%(8/33),口炎12.1%(4/33),不良反应较轻,予以对症处理后均缓解。29例(87.88%)存活,其中ⅢB期5例,Ⅳ期24例。中位生存期为32个月(95%可信区间20～39个月)。结论盐酸埃克替尼治疗晚期非小细胞肺癌临床疗效显著,可有效改善患者免疫功能,延长患者生存期限,安全性高,值得推广应用。

Objective To investigate the clinical effects of icotinib hydrochloride in patients with advanced non-small cell lung cancer and its effect on immune function.Methods Thirty-three patients admitted to our hospital from May 2013 to December 2017 were treated with oral icotinib hydrochloride.The clinical efficacy,immune function,adverse reactions and survival time of the patients were observed.Results The effective rate of stageⅢB was 33.33%,and the control rate was 83.33%,which was higher than those of stageⅣ(29.63%and 70.37%)(P<0.05).After treatment,CD3^+,CD4^+and CD4^+/CD8^+were significantly higher than those before treatment,while CD8^+was significantly lower than that before treatment(P<0.05).The adverse reactions after treatment were 39.4%(13/33)for rash,30.3%(10/33)for nausea and vomiting,21.2%(7/33)for diarrhea,24.2%(8/33)for loss of appetite,and 12.1%for stomatitis(4/33),which were all mild,and alleviated after symptomatic treatment.29 cases(87.88%)survived,including 5 cases in stageⅢB and 24 cases in stageⅣ.The median survival time was 32 months(95%confidence interval 20 to 39 months).Conclusion The clinical efficacy of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer is significant,which can effectively improve the immune function of patients,prolong the survival period of patients,and has high safety.It is worthy of promotion and application.